IGC-M3 targets the disease on four fronts, showing promise in cellular models - POTOMAC, MD / ACCESS Newswire / August 5, 2025 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a ...

Conformationally constrained 2-pyridone analogue 2 is a potent Met kinase inhibitor with an IC50 value of 1.8 nM. Further SAR of the 2-pyridone based inhibitors of Met kinase led to potent 4-pyridone ...